Remix Therapeutics, Inc. announced updated Phase 1 data from its ongoing ARIA Phase 1/2 clinical trial of REM-422, an oral MYB mRNA degrader, during a late-breaking presentation at the 2026 EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics. The data, presented on November 19, 2026, focuses on patients with adenoid cystic carcinoma (ACC).

The study evaluated REM-422 in a Phase 1/2, open-label, non-randomized, multicenter trial (NCT06118086) involving patients with recurrent, metastatic, or unresectable ACC. As of August 24, 2026, 69 patients had been enrolled in the Phase 1 study, including 60 efficacy-evaluable patients. The trial includes a Dose Escalation Phase to determine the maximum tolerated dose and a Dose Expansion Phase to evaluate the recommended Phase 2 dose (RP2D) in biomarker-positive patients.

Key findings from the analysis include:

MYB biomarker status emerged as a key predictor of clinical and pharmacodynamic response. No objective responses were observed among biomarker-negative patients. The potentially registrational Phase 2 study enrolling biomarker-positive patients treated at the 24 mg dose is expected to complete enrollment by the end of the year.

REM-422 is a first-in-class oral small molecule designed to bind a poison exon within MYB mRNA, inducing degradation of the transcript and reducing MYB protein expression. The U.S. Food and Drug Administration has granted REM-422 Orphan Drug Designation for ACC and AML and Fast Track designation for ACC.